European Lead Factory

What European Lead Factory does

European Lead Factory (ELF) is a Netherlands-based public-private partnership founded in February 2013 and managed by the non-profit foundation Stichting Lygature to provide academic researchers, small and medium-sized enterprises (SMEs), and pharmaceutical companies with access to early-stage drug discovery infrastructure that would otherwise only be available inside large pharma R&D organizations. Operated as a consortium of approximately 30 partners, ELF combines seven EFPIA pharmaceutical companies (Bayer, UCB, Merck Healthcare KGaA, Janssen, AstraZeneca, Sanofi, Servier, Grünenthal), specialist contract research SMEs (Taros, Sygnature Discovery, Edelris, Symeres, BioAscent, Pivot Park Screening Centre), and academic centres (University of Dundee, University of Oxford, Leiden University, and others).

The platform's core asset is the Joint European Compound Library (JECL) of approximately 400,000 unique drug-like screening compounds assembled from previously inaccessible proprietary pharmaceutical collections and expanded through crowdsourced chemistry proposals contributing the Public Compound Collection (~190,000 compounds). ELF operates European Screening Centre infrastructure at Pivot Park Screening Centre in Oss (Netherlands) and the University of Dundee in Newhouse (UK), offering ultra-high-throughput screening across multiple detection modalities (fluorescence, luminescence, real-time kinetics) and an award-winning cloud-based Honest Data Broker (HDB) informatics system that manages intellectual property across the consortium. Service deliverables include Qualified Hit Lists (QHL) of up to 50 compounds and follow-up Improved Hit Lists (IHL) with medicinal chemistry support; over 300 programmes and 10,000+ hit compounds were delivered over 11 years alongside 106 peer-reviewed publications.

ELF does not operate as a commercial enterprise. Services are provided free of charge to approved programme owners under the Innovative Medicines Initiative (IMI), with a total project budget of approximately €196 million (€80M from the European Commission's FP7/Horizon 2020, €91M of in-kind contributions from EFPIA companies, €25M from non-EFPIA participants) supplemented by €6.3M for the ESCulab extension. After 11 years of operation the project formally concluded with its Final Consortium Meeting in November 2023.

Name

European Lead Factory

Legal name

Stichting Lygature

Website

https://europeanleadfactory.eu

Company type

Private

Founded year

2013

Operating status

Operating

Headcount range

51–100 employees

Short description

The European Lead Factory is a Netherlands-based public-private partnership consortium providing free high-throughput screening, a 400,000-compound Joint European Compound Library, and medicinal chemistry support to European academic researchers, SMEs, and pharmaceutical partners, funded by the EU's Innovative Medicines Initiative.

Ownership category

akta.pro rank

Product category

Drug Discovery Services

NAICS

Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

High-Throughput Screening & Assay Platforms (HTS/HCS, phenotypic screening) (HLAAAIAA)

akta.pro secondary industries

Drug Discovery (Target ID/Validation & Hit Discovery) (HLAIALAA), Lead Optimization & Preclinical Candidate Selection (HLAIALAB)

Keywords

• High-throughput screening
• Drug discovery services
• Compound library access
• Lead generation platform
• Medicinal chemistry services

Headquarters

HQ city

Utrecht

HQ country

Netherlands

HQ region

Europe

Offices4 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Infrastructure, Technology or R&D, Operations, Marketing or Sales

Revenue model

1. Grant funding and in-kind contributions: Funded under the European Innovative Medicines Initiative (IMI). Total project budget approximately €196 million, with €80 million from the European Commission (FP7/Horizon 2020), €91 million of in-kind contributions from EFPIA companies, and €25 million from non-EFPIA participants. Services are provided free of charge to eligible programme owners.

Pricing tiers

Go-to-market motion2 records

Distribution channels1 record

Marketing channels5 records

Core offering

European Lead Factory provides free high-throughput screening services for early-stage drug discovery to academic researchers, SMEs, and pharmaceutical companies. The platform combines a Joint European Compound Library of over 400,000 drug-like compounds with ultra-HTS screening infrastructure, assay development support, and medicinal chemistry expertise, delivering Qualified Hit Lists (QHL) and Improved Hit Lists (IHL) to programme owners through a structured application process funded by the Innovative Medicines Initiative.

Product overview

The European Lead Factory is a public-private partnership offering a comprehensive drug discovery platform centered on the Joint European Compound Library (JECL), which contains over 400,000 drug-like screening compounds sourced from pharmaceutical companies and crowdsourced from academia. The platform is complemented by the European Screening Centre providing ultra-high throughput screening capabilities, the Honest Data Broker informatics system for IP management, and full service support including assay development and medicinal chemistry. The core offering includes screening programme access, Qualified Hit Lists (QHL) as primary deliverables, and follow-up Improved Hit Lists (IHL) for hit optimization. The platform serves academic researchers, SMEs, and pharmaceutical partners across Europe.

Differentiator

Problem solved

Functional benefit

Brands

• Joint European Compound Library (JECL): A compound library combining proprietary collections from major pharmaceutical companies with crowdsourced innovative chemical libraries, containing over 400,000 compounds
• Public Compound Collection (PCC)
• European Screening Centre
• Honest Data Broker (HDB)

Products and services

• Joint European Compound Library (JECL) A compound library containing over 400,000 unique drug-like screening compounds compiled from previously inaccessible proprietary collections of major pharmaceutical companies and expanded through crowdsourcing of chemical library ideas.
• Public Compound Collection (PCC) A collection of around 190,000 compounds designed based on crowdsourced chemistry proposals from academic and SME experts, integrated as part of the Joint European Compound Library.
• European Screening Centre Screening infrastructure providing ultra-high throughput screening (uHTS) facilities across multiple European sites, supporting multiple detection methods including fluorescence, luminescence, and real-time calcium kinetics for screening compound libraries against biological targets.
• Honest Data Broker (HDB) A cloud-based informatics system developed to balance intellectual property and scientific requirements of consortium partners regarding unique HTS screening and triage workflow. Award-winning software published in Drug Discovery Today.
• Qualified Hit List (QHL) A deliverable of up to 50 compounds that show activity against a submitted target and fulfil additional selection criteria, provided to programme owners for hit optimization and drug development.
• Improved Hit List (IHL) Follow-up phase deliverable that includes re-synthesis of selected QHL compounds, mechanism of action evidence, biochemical and biophysical profiling, and hit expansion around promising chemotypes.
• Target Programme Screening Screening services for biological targets submitted by academic institutions and SMEs against the Joint European Compound Library, with professional assay development assistance and medicinal chemistry support provided through the European Screening Centre.
• Assay Development Support Professional assistance with assay development for high throughput screening, including consultation on assay optimization and validation, provided to programme owners through the European Screening Centre.

Quantifiable outcome

• Over 10,000 hit compounds delivered to programme owners for further optimization and drug development
• +3 more outcomes

Named customers10 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

38 partnerships are on record, tiered core, secondary and minor.

• BayercoreStrategic or Co-development Partner · 7 February 2013Bayer HealthCare, a global enterprise in healthcare and medical products, is one of the seven EFPIA partners contributing proprietary compounds and expertise to the Joint European Compound Library. Bayer's Stefan Jaroch served as Project Coordinator (from 2015).
• LygaturecoreStrategic or Co-development PartnerFormerly Top Institute Pharma (TI Pharma), Lygature is a not-for-profit organization that manages the European Lead Factory and European Screening Centre. Based in Leiden, Netherlands.
• University of DundeecoreStrategic or Co-development PartnerProject leader Professor Jason Swedlow. Home to European Screening Centre location and National Phenotypic Screening Centre. Professor Andrew Hopkins (exscientia founder) affiliated with this institution.
• National Phenotypic Screening Centre (NPSC)coreStrategic or Co-development PartnerLed by Professor Jason Swedlow, NPSC is a key academic partner in the consortium providing phenotypic screening expertise.
• University of OxfordcoreStrategic or Co-development PartnerLed by Dr Nicola Burgess-Brown. Key contributor to antibacterial screening, crystal exploration, and natural-like small molecules libraries. Professor Chris Schofield leads antibiotic resistance programme.
• UCBcoreStrategic or Co-development PartnerEFPIA partner contributing to screening programmes. Jeremy Davis, Director of Medicinal Chemistry, has received Qualified Hit Lists from ELF screening.
• Merck Healthcare KGaAcoreStrategic or Co-development PartnerEFPIA partner where Dirk Finsinger serves as Director in Medicinal Chemistry with experience in Oncology and Immunology hit identification.
• JanssencoreStrategic or Co-development PartnerEFPIA partner contributing proprietary compounds and participating in collaborative screening through the Joint European Compound Library.
• AstraZenecacoreStrategic or Co-development PartnerEFPIA partner contributing proprietary compounds and participating in collaborative screening programmes through the consortium.
• SanoficoreStrategic or Co-development PartnerEFPIA partner contributing proprietary compounds. Sponsored prize for best oral presentation at PostDoc Learnings and Achievements meeting.
• ServiercoreStrategic or Co-development PartnerEFPIA partner contributing proprietary compounds and participating in collaborative screening through the Joint European Compound Library.
• Pivot Park Screening Centre (PPSC)coreStrategic or Co-development PartnerDutch screening centre in Oss providing ultra-HTS facilities. Stan van Boeckel serves as Chief Scientific Officer. Hosts Assay Development Fund for Dutch scientists.
• TaroscoreStrategic or Co-development PartnerContract research company in Dortmund, Germany. Dr Dimitrios Tzalis is CEO and ELF Head of Chemistry. Developed software suite 'Taros Gate'. Contributed to milestone of 10,000 molecules.
• Sygnature DiscoverycoreStrategic or Co-development PartnerSME chemistry partner contributing to library synthesis as part of the chemistry consortium (Edelris, Mercachem, Sygnature, Syncom, Taros).
• EdelriscoreStrategic or Co-development PartnerSME chemistry partner achieving milestone of 10,000 molecules prepared for the ELF project with University of Leeds and Technical University of Denmark.
• SymerescoreStrategic or Co-development PartnerSME chemistry partner contributing to library synthesis within the chemistry consortium.
• BioAscentcoreStrategic or Co-development PartnerSME partner in the consortium providing compound management and screening services.
• GrünenthalcoreStrategic or Co-development PartnerEFPIA partner contributing proprietary compounds and participating in collaborative screening through the Joint European Compound Library.
• University of NottinghamsecondaryStrategic or Co-development PartnerFormer partner led by Dr Robert Stockman and Prof Chris Moody. Contributed chemistry expertise to the consortium.
• Leiden UniversitysecondaryStrategic or Co-development PartnerManaging entity of the public-private partnership. Prof Mario van der Stelt leads DAGL lipase research with ELF support developing lead series with nM potency.
• Leiden University Medical CentersecondaryStrategic or Co-development PartnerFormer partner led by Prof Huib Ovaa, involved in early ELF screening programmes and chemical biology research.
• Max Planck Institute of Molecular PhysiologysecondaryStrategic or Co-development PartnerFormer partner led by Prof Herbert Waldmann and Dr Kamal Kumar, contributing to innovative scaffold development.
• Radboud University NijmegensecondaryStrategic or Co-development PartnerFormer partner led by Prof Florian Rutjes, contributing to drug discovery chemistry.
• University of GroningensecondaryStrategic or Co-development PartnerFormer partner led by Prof Alexander Dömling in the Department for Drug Design.
• Technical University of DenmarksecondaryStrategic or Co-development PartnerFormer partner led by Prof Mads H. Clausen, contributing to scaffold synthesis with Edelris and University of Leeds.
• VU University AmsterdamsecondaryStrategic or Co-development PartnerFormer partner led by Prof Romano V.A. Orru and Dr Eelco Ruijter, contributing multicomponent reaction expertise.
• University Duisburg-EssensecondaryStrategic or Co-development PartnerFormer partner led by Prof Markus Kaiser, contributing to chemical biology research.
• University of LeedssecondaryStrategic or Co-development PartnerFormer partner led by Prof Adam Nelson, contributing to innovative scaffold development with Edelris and Technical University of Denmark.
• Medicines for Malaria Venture (MMV)coreStrategic or Co-development PartnerNon-profit partnership supporting development of medicines for malaria and neglected diseases. Five ELF programmes dedicated to MMV targets.
• Drugs for Neglected Diseases InitiativecoreStrategic or Co-development PartnerNon-profit organization working on neglected tropical diseases. Dr Eric Chatelain, Head of Drug Discovery, encourages scientists to submit NTD programmes to ELF.
• Scottish Universities Life Sciences Alliance (SULSA)secondaryStrategic or Co-development PartnerEstablished Assay Development Fund to help Scottish academics develop ELF-standard assays with expertise at ESC Newhouse (University of Dundee).
• Fundación BotínminorStrategic or Co-development PartnerSpanish foundation committed to economic and social development funding biomedical research. Published interview with Jon de Vlieger (Lygature) highlighting ELF opportunities for public researchers.
• Effecta PharmaminorStrategic or Co-development PartnerDutch biotech company for which ELF commenced drug screening campaign for dengue viral target at European Screening Centre locations.
• NTRC (Netherlands Translational Research Centre)secondaryStrategic or Co-development PartnerDutch biotech SME at Pivot Park, Oss. First SME to receive Qualified Hit List from ELF using NTRC's NFK GreenScreen assay technology for TDO target.
• CELLIPSEminorStrategic or Co-development PartnerFrench drug discovery company awarded exclusive HTS research program to screen ELF's joint compound library on innovative therapeutic target for leukemia.
• SelvitaminorStrategic or Co-development PartnerPolish biotech company whose epigenetic oncology project became the first Polish drug target programme selected by ELF.
• Center for Applied Medical Research (CIMA)minorStrategic or Co-development PartnerResearch center at University of Navarra, Spain. First Spanish programme selected by ELF targeting epigenetic mechanism for cancer treatment.
• i3S (Institute for Research and Innovation in Health)minorStrategic or Co-development PartnerPortuguese research institute whose Parasite Disease Group became first Portuguese team to introduce a project into ELF targeting Leishmania enzyme.

Scale indicators8 records

Recent moves5 records

Expansion highlights5 records

Direct peers

• Open Targets: Public-private partnership between EMBL-EBI, GSK, Wellcome Sanger, and pharma partners for systematic drug target identification and prioritisation, sharing the same IMI-era open-innovation ethos and multi-stakeholder governance as ELF.
• Medicines for Malaria Venture (MMV): Public-private partnership funding antimalarial drug development through pharma and academic collaboration; ELF ran five dedicated MMV programmes, evidencing directly overlapping screening programme workflows and consortium model.
• LifeArc: UK self-funded medical research charity (formerly MRC Technology) providing translational drug discovery, antibody engineering, and HTS services to academia and industry, with analogous mission of bridging academic research into pharmaceutical development.
• Lead Discovery Center GmbH: German translational drug discovery centre spun out of Max Planck Innovation with a similar public-private model offering assay development, HTS, and medicinal chemistry services to academic and industry partners in early-stage drug discovery.
• Structural Genomics Consortium (SGC): Public-private partnership supporting open-access drug discovery through target identification, chemical probes, and antibody generation, with similar funding model from public sources and pharma partners and analogous consortium governance.
• Drugs for Neglected Diseases initiative (DNDi): Not-for-profit drug R&D organisation addressing neglected tropical diseases through public-private partnerships, directly comparable to ELF's NTD programme arm and partner relationship, with overlapping free/waived service models.

Broad incumbents

• Evotec SE: Commercial CRO offering end-to-end drug discovery including HTS, assay development, and medicinal chemistry services to academic and industry clients globally, providing a commercial benchmark for services ELF provides free of charge.
• Scripps Research - Calibr: Translational research division of Scripps Research operating 'ReFRAME' open-access drug repurposing library and discovery services, similar open-access philosophy and academic-pharma hybrid model.
• NIH National Center for Advancing Translational Sciences (NCATS): US government-funded translational sciences platform operating HTS, assay development, and medicinal chemistry capabilities for academic researchers, comparable in scale and open-access mission though much larger and federally funded.
• Broad Institute (Chemical Biology & Therapeutics Science): Large US academic drug discovery platform with deep HTS, chemical biology, and medicinal chemistry capabilities serving academic collaborators, analogous mission though much broader scientific portfolio and more permanent funding base.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/euleadfactory
• YouTubeyoutube.com/channel/UCBve3AHxyhFSC0ou8C9DZkg
• LinkedInlinkedin.com/company/european-lead-factory

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about European Lead Factory